38 results about "Single administration" patented technology

Described herein are long-acting injectable formulations for the treatment or prevention of a parasitic infestation or infection in an animal. The formulation contains a parasiticidal isoxazoline active agent; and castor oil or a combination of castor oil and a second natural oil. The amount of castor oil in the formulation or the combination of castor oil and the second natural oil is at least 40% (w / w). The formulation can be in the form of a solution or a suspension, and physically stable at standard ambient temperature and pressure for at least 1 month. Typically, the formulation is at least 80% effective at treating or preventing infestation by fleas and / or ticks for at least 6 months following a single administration to the animal.

The invention provides a memantine derivative or a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of the memantine derivative, and application of the memantine derivative in preparation of drugs for preventing and / or treating central nervous diseases, especially Alzheimer's disease, Parkinson's disease or other neurodegenerative diseases. The compound disclosed by the invention is small in water solubility, can be well prepared into a suspension preparation, has a relatively low dissolution speed in a living body, can achieve the effect of lasting the drug effect for several weeks after single administration, reduces the medication frequency of a patient, improves the compliance of the patient, also ensures the curative effect, and has a relatively good application prospect.

Engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains have been developed. Compositions and methods for providing protective immune responses against influenza are provided. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Methods for delivering co-stimulatory molecules, growth factors, adjuvants and / or cytokines together with the non-replicating influenza viruses are also provided.

The invention provides a sustained-release and quick-release coated tablet and a preparation method thereof, and belongs to the technical field of biological medicines. The outer layer of the core-coated tablet is the quick-release layer, the inner layer of the core-coated tablet utilizes the coating to prolong release, and the core-coated tablet is used as the slow-release layer to realize double-phase release of drugs, so that time-sharing release and outer-layer quick release after single administration are realized, drug peak concentration and effective drug concentration can be reached in a short time after administration, and the inner layer is slowly released by virtue of the coating material; the sustained-release rate is not influenced by the pH value of the intestinal tract, the force of peristalsis and extrusion of gastrointestinal tracts can be borne, the problem that the sudden release rate of the medicine is large in deviation is avoided, and the sustained-release preparation is safer and more effective.

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The present invention provides an injectable depot composition comprising enavogliflozin and low-dose liraglutide. A combination regimen of enavogliflozin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared with the single administration of either drug. Furthermore, compared with the single administration of liraglutide, the administered dose of liraglutide can be reduced, and thereby the direct causes of gastrointestinal and cardiovascular side effects of liraglutide can be mitigated. Furthermore, the present invention has the additional advantage of providing an effect for alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through combined administration with enavogliflozin.Furthermore, the depot composition of enavogliflozin and liraglutide according to the present invention can significantly improve treatment convenience and treatment compliance for patients compared to existing liraglutide formulations, which are injected subcutaneously once daily, by unifying the route of administration and increasing the cycle of administration.

The present application belongs to the technical field of medicine, and relates to a kind of pharmaceutical composition and its application in preparation for treating or preventing liver fibrosis drug. A kind of pharmaceutical composition for treating or preventing liver fibrosis, the pharmaceutical composition includes as active ingredient the protocatechuic acid (PCA) and gimalin (GER). The present application first confirms that protocatechuic acid and gimalin combined application has significant synergistic effect in the treatment of liver fibrosis, and its curative effect is better than any single compound single administration, can more effectively reduce liver injury index, improve liver pathological morphology, reduce intrahepatic collagen deposition. Based on its clear mechanism of action, the composition of the present application is especially suitable for treating liver fibrosis related to abnormal expression of RIPK3.

The invention discloses a liposome preparation prepared from a benzoyl guanidine derivative LY104 crystal form as well as a preparation method and application of the liposome preparation, and belongs to the technical field of medicines. The invention provides a liposome for inflammatory lung diseases, which takes LY104 and a novel crystal form thereof as active ingredients. The liposome prepared by the invention is good in stability, stable in membrane drug loading, and suitable for atomization drug delivery, and the particle size can be controlled to be 50-200nm. Meanwhile, the liposome preparation provided by the invention can delay drug release, prolong the onset time, improve the tolerated dose of single administration, reduce drug irritation, and can be used for treating inflammatory lung diseases, after being freeze-dried, the liposome preparation provided by the invention is dispersed in saline water to be atomized and inhaled, so that the bitter taste of the drug can be greatly covered, and the bioavailability of the drug is improved. The lipidosome preparation has the advantages that drug irritation is reduced, drug bioavailability is improved, patient compliance is improved, the lipidosome preparation can optimize the in-vivo metabolic process of the benzoyl guanidine derivative, the curative effect of the benzoyl guanidine derivative on treating inflammatory lung diseases is enhanced, and the application prospect is wide. The liposome preparation provided by the invention can be used for treating inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease and the like in a more targeted manner, and has a wide market application prospect.

The invention discloses lidocaine hydrochloride-containing sodium hyaluronate gel for injection and a preparation method of the lidocaine hydrochloride-containing sodium hyaluronate gel, and belongs to the technical field of sodium hyaluronate gel. Comprising the following steps: preparing an alkaline sodium hyaluronate composite solution, a cross-linking agent composite solution and a gel block, dialyzing, granulating to obtain gel particles, preparing a lidocaine composite solution, and mixing to obtain the lidocaine hydrochloride-containing sodium hyaluronate gel for injection. According to the lidocaine hydrochloride-containing sodium hyaluronate gel for injection, the lidocaine hydrochloride can quickly reach 3.3 mu g / mL or above within 10 min after administration, the concentration can be stably maintained for 8 h or above, the peak concentration lasting time reaches 5 h or above, the single administration concentration does not need to be increased or the administration frequency does not need to be increased, and the lidocaine hydrochloride-containing sodium hyaluronate gel for injection can be used for injection. The requirements of clinical injection operation and local analgesia within a period of postoperative time can be met.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Use of a flurbiprofen axetil (FPA) in preparing a pharmaceutical composition for fever relief in a patient through an intravenous administration route is provided, where the pharmaceutical composition includes FPA at a content of 10 mg to 40 mg, preferably 10 mg to 35 mg, 15 mg to 35 mg, and 15 mg to 30 mg, 15 mg, and 30 mg. The pharmaceutical composition can be safely and effectively used for fever relief in an adult patient. Surprisingly, the pharmaceutical composition has a comparable antipyretic effect and duration to a pharmaceutical composition with high-content FPA, but the pharmaceutical composition with low-content FPA has less adverse reactions. Compared with ibuprofen injections, a single administration of the low-dosage FPA provided by the present disclosure can maintain an antipyretic effect for 6 hours to 10 hours or more, which significantly reduces the administration frequency and improves the compliance of a patient.

The invention provides a composition for treating neurasthenia as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: mixing an oxazepam derivative or physiologically acceptable salt thereof with traditional Chinese medicine polysaccharide, and adding other materials to prepare the sustained-release tablet. The composition for treating neurasthenia has the advantages that the medicine release time is prolonged, the patient compliance is obviously improved, the single administration dosage can be reduced by controlling the release rate, meanwhile, the composition is combined with the traditional Chinese medicine polysaccharide, the safety is better, the composition is milder and non-irritant, the composition is released in a targeted intestinal tract, the intestinal-brain axis is activated, the stability of the preparation is improved on the whole, and the application prospect is wide. Wide application prospects are realized.

In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

The invention provides application of a targeted folate receptor antibody coupling medicine in colorectal cancer and humanization of the targeted folate receptor antibody coupling medicine. Specifically, the invention provides an application of a drug conjugate formed by coupling an anti-FOLR1 antibody and VcMMAE in treatment of colorectal cancer. In addition, the invention also provides application of the combined combination of the drug conjugate and gemcitabine in colorectal cancer treatment, and compared with independent administration, the combined combination of the drug conjugate and gemcitabine has a better inhibition effect on colorectal cancer.

The invention discloses a TPRN gene therapy system driven by a coProB2 promoter and application of the TPRN gene therapy system, and belongs to the field of biological medicine. Specifically, the invention relates to a nucleic acid, which comprises a coProB2 promoter and mouse TPRN-cDNA, and an expression vector formed by the nucleic acid, and the nucleotide sequence of the coProB2 promoter is SEQ ID NO.1. The invention also relates to a preparation method of the coProB2 promoter. According to the expression vector constructed by the invention, after single administration, the ABR threshold value of a DFNB79 model mouse is recovered to a wild type level (30dB SPL), the curative effect lasts for at least 3 months, the partial rescue effect of the expression vector is obviously superior to that of a broad-spectrum promoter (such as CAG and CMV173), and functional healing is realized; meanwhile, subcellular structure repairing can be achieved, and cross-species safety is achieved.

In one aspect, the present description provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present description provides a method for administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

The invention relates to hepatic fibrosis intervention, and provides a pharmaceutical composition for treating and / or preventing hepatic fibrosis related to TET2 function deficiency type myeloid cells and application of the pharmaceutical composition. The composition comprises: (a) an inhibitor or antagonist for inhibiting chemotactic signals mediated by CCL2 and / or CCL8 and CCR2 and / or CCR3; and (b) an IL-6 pathway inhibitor. Preferably, (a) is Bindarit or a pharmaceutically acceptable salt thereof, and (b) is an IL-6 neutralizing antibody or an IL-6 receptor antibody. According to the composition, by reducing mononuclear cell recruitment / proinflammatory mononuclear cell source macrophage infiltration and blocking IL-6 mediated hepatic stellate cell activation, collagen deposition is relieved, and fibrosis indexes such as alpha-SMA and Col1a1 are reduced. Animal experiments show that in a CCl4-induced myeloid Tet2 deletion mouse model and an old-age chimeric model, combined administration is superior to single administration.

The invention discloses a KRAS targeted protein degradation chimera and application thereof.The constructed targeted protein degradation chimera can effectively target KRAS mutants which are traditionally considered to be'non-patent medicine ', and the mutants are generally lack of deep binding pockets and are difficult to be effectively recognized by small-molecule inhibitors; the chimera shows higher target affinity and wider target coverage range, and meanwhile, the off-target risk is remarkably reduced; long-acting expression can be realized in vivo based on a plasmid DNA or mRNA delivery strategy, so that the drug delivery system has the treatment potential of'one-time administration and lasting degradation ', and is expected to greatly improve the medication compliance and the treatment effect.

The invention provides application of blood nourishing oral liquid combined with drospirenone ethinylestradiol in clinical symptoms and endometrial receptivity after an induced abortion operation, and belongs to the technical field of biological medicine. According to the application of the blood nourishing oral liquid and the drospirenone ethinylestradiol in preparation of the medicine for improving the clinical symptoms after the induced abortion operation, the result of the embodiment shows that compared with a drospirenone ethinylestradiol single administration group, the combined administration group has the advantages that the vaginal bleeding duration is shorter, the vaginal bleeding amount is smaller, the abdominal pain degree is lower, and the clinical symptoms after the induced abortion operation can be improved. The dominant follicle size, the endometrial thickness, the endometrial volume, the type A endometrial rate, the type III endometrial and the ratio of the endometrial-muscular layer binding band are all higher than those of a control group, and the aneurysm hemodynamic indexes are all lower than those of a single administration group. Therefore, the blood-nourishing oral liquid combined with drospirenone ethinylestradiol can effectively improve postoperative clinical symptoms of patients, promote follicle development and improve endometrial receptivity.

The application discloses application of a migration body in preparation of a medicine for inhibiting osteoclast differentiation or promoting osteogenesis. The application significantly improves the secretion amount of the migration body by optimizing cell culture conditions, realizes large-scale preparation, and greatly reduces production cost. The application also enriches active ingredients in the migration body by pressure stimulation, so that the migration body has more excellent effect of promoting bone defect repair. In addition, the migration body has larger size and a stable film structure, prolongs in-vivo retention time, realizes long-acting repair by single administration, and further solves the long-acting and clinical transformation problems. The migration body has wide application prospect in the field of bone defect repair.

The present application provides a kind of targeting folate receptor antibody conjugated drug in colorectal cancer and its humanization.The specific application provides the application of the drug conjugate of anti-FOLR1 antibody and VcMMAE conjugation in the treatment of colorectal cancer.In addition, the present application also provides the application of the combination of the drug conjugate and gemcitabine in the treatment of colorectal cancer, and the combination of the drug conjugate and gemcitabine has better inhibitory effect on colorectal cancer than single administration.

The present invention relates to: a pharmaceutical composition for preventing or treating cancer, comprising an SOS1 inhibitor and a KRAS inhibitor; a combination for co-administration; a kit; and uses thereof, and can exhibit a remarkably excellent effect on the prevention and / or treatment of cancer compared to single administration.

In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

The application discloses a glycosylated hydroxypyridinone ligand and a preparation method and application thereof. The glycosylated hydroxypyridinone ligand has excellent coordination capacity with uranium ions, thorium ions and the like, and can realize optimization of the decontamination effect under single administration through intraperitoneal or tail vein administration, and has extremely application prospects in preparation of actinide decontamination agents. Meanwhile, the preparation method is simple, the synthesis condition is mild, and the yield is high, and is suitable for large-scale production.

The present invention relates to a sustained-release pharmaceutical composition using a GLP-1 receptor agonist. Specifically, microparticles comprising semaglutide are prepared using a 5-hydroxydopamine-modified self-crosslinkable hyaluronic acid derivative (SAMH) as a carrier, and the semaglutide is gradually released over a long period of time upon injection into the body, thereby providing excellent effects on blood glucose control and weight management. The sustained-release pharmaceutical composition according to the present invention maintains a low viscosity before administration to the human body, thus being easily administered by injection, and is self-crosslinked and hydrogelated after administration to the human body, and thus can maintain the pharmacological effect of the semaglutide for a long period of time with only a single administration.

In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

In one aspect, the disclosure provides a formulation comprising a hyaluronidase and a therapeutically effective amount of an active ingredient. In another aspect, the disclosure provides a method of administering a high volume of formulation in a single administration to treat a disease or condition in a subject.